Business
BioMarin Announces Publication in New England Journal of Medicine of One-Year Results from Phase 3 Pivotal Trial with Valoctocogene Roxaparvovec Gene Therapy in Adults with Severe Hemophilia A
New England Journal of Medicine Publishes Editorial: Prepare the Way for Hemophilia A Gene Therapy Significantly Reduced Bleeding and Factor VIII Utilization
About this update from Biomarin Pharmaceutical Inc.
[{"type":"text","content":"New England Journal of Medicine Publishes Editorial: Prepare the Way for Hemophilia A Gene Therapy\nSignificantly Reduced Bleeding and Factor VIII Utilization Compared to Baseline Factor VIII Prophylactic Therapy\nMean Annualized Bleeding Rate (ABR) Reduced by 84% (p-value","length":406,"tagName":"div"}]